A variant of estrogen receptor-α, ER-α36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis

HAO DENG1, XUAN HUANG1, JUN FAN1, LIUBAI WANG1, QIN XIA1, XIUPING YANG2, ZHAOYI WANG3 and LIJIANG LIU1,4

1Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, Hubei Province 430056; 2Department of Pathology, Xiehe Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei Province 430030, P.R. China; 3Departments of Medical Microbiology and Immunology and Pathology, Creighton University Medical School, 2500 California Plaza, Omaha, NE 68178, USA; 4Jiangda Pathology Center, Jianghan University, Wuhan, Hubei Province 430056, P.R. China

Received December 31, 2009; Accepted March 9, 2010

DOI: 10.3892/or_00000842

Abstract. Gastric cancer is one of the most common cancers in the world; almost two-thirds of gastric cancer cases and deaths occur in less developed regions. The molecular and cellular events during development of gastric cancer remain unclear. Herein, we examined the expression of ER-α36, an ER-α variant, in established gastric cancer cell lines and specimens from 22 gastric cancer patients. RT-PCR, Western blot and immunohistochemistry methods were used to assess expression levels of ER-α36. ER-α36 localization in gastric cancer cells was determined with an immunofluorescence assay. Both mRNA and protein of ER-α36 were detected in all established gastric cancer cell lines examined. Higher levels of ER-α36 mRNA were expressed in 17 of 22 (77.27%) tumor specimens examined compared to the paired normal tissues (p<0.05). ER-α36 protein was expressed mainly on the plasma membrane and in the cytoplasm of the established gastric cancer cells. ER-α36 expression is highly correlated with lymph node metastasis in human gastric cancer (P<0.05). The estrogen receptor variant ER-α36 is highly expressed in human gastric cancer. ER-α36 expression may be used as a predictive marker for lymph node metastasis of gastric cancer.

Introduction

Estrogen signaling is pivotal in the establishment and maintenance of reproductive function in men and women. It is also involved in normal development and physiology of bone, cardiovascular and neuronal systems. It is believed that dysregulated estrogen signaling is involved in the initiation and development of neoplasia in at least breast and endometrial cancers (1). However, the involvement of estrogen signaling in other types of human cancer has not been well established.

The diverse physiological functions of estrogens are mediated by specific nuclear receptors designated as estrogen receptors (ERs). In 1986, the cloning of the estrogen receptor (ER) was first reported (2,3). Until 1996, it was assumed that there was only one ER responsible for all of the physiological and pharmacological effects of natural and synthetic estrogens and antiestrogens. However, in 1996, a second ER was cloned (4). Currently, the first ER discovered is referred to as ER-α, while the second is called ER-β.

ER-α and ER-β share a common structural architecture (5,6). Both are composed of three independent but interacting functional domains: the N-terminal A/B domain, the C or DNA-binding domain, and the D/E/F or ligand-binding domain. The N-terminal domain of ER-α encodes a ligand-independent activation function (AF-1), a region involved in interaction with co-activators, and transcriptional activation of target-genes. The DNA-binding domain or C domain contains a two zinc-finger structure, which plays an important role in receptor dimerization and binding to specific DNA sequences. The C-terminal E/F domain is a ligand-binding domain that mediates ligand binding, receptor dimerization, nuclear translocation, and a ligand-dependent transactivation function (AF-2).

It has been well documented that the ERs are ligand-activated transcription factors that stimulate target gene transcription (1). Stimulation of target gene expression by ERs in response to estrogens is prevailing thought to be responsible for cell proliferation. Despite the clarity with which ERs have been shown to act as transcription factors, it became apparent that not all of the physiological effects mediated by estrogens are accomplished through a direct
effect on gene transcription. Another signaling pathway (also known as a ‘non-classic’, ‘non-genomic’ or ‘membrane signaling’ pathway) exists that involves cytoplasmic proteins, growth factors and other membrane-initiated signaling pathways (7).

Previously, we identified and cloned a novel variant of ER-α, ER-α36, with a molecular weight of 36 kDa (8,9). ER-α36 lacks both transactivation domains AF-1 and AF-2 of the 66-kDa full-length ER-α (ER-α66) (8,9). The transcripts of ER-α36 are initiated from a previously unidentified promoter located in the first intron of the ER-α66 gene (8). Further research found that ER-α36 is subjected to a transcriptional regulation totally different from the ER-α66 (10).

Estrogens have been proposed to provide protection against gastric cancer of women before menopause (11); the incidence of gastric cancer is higher in men than in women before menopause (12). The incidence of gastric cancer in women after menopause reaches a level similar to men (13). The incidence of gastric cancer of women before menopause (11); the correlation between ER-α36 expression in human gastric cancer of women before menopause (13). These findings suggested an involvement of estrogen signaling in protection against human gastric cancer. Tokunaga et al (14) first reported ER-α66 expression in human gastric cancer. Since then, a number of laboratories have reported expression of ER-α in gastric cancer and correlated ER status to tumor grade (15,16). In addition, the effects of estrogens on the growth of human gastric cancer xenografts in nude mice were studied (17). It was found that ER-α66 was expressed mainly in the cytoplasm of gastric carcinoma cells while it is predominantly expressed in the cell nuclear of breast cancer cells (18).

In the present study, we examined the expression and localization of ER-α36 in established gastric cancer cells and specimens from gastric cancer patients. We also examined correlations between ER-α36 expression and lymph node metastasis of human gastric adenocarcinoma.

Materials and methods

Cell culture. Human gastric adenocarcinoma cell lines BGC-823 and SGC7901 were obtained from Cell Center of Basic Medicine, Chinese Academy of Medical Sciences (Beijing, China). Human gastric cancer cell line AGS and breast cancer cell line MCF-7 were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Human gastric cancer cell line MKN-45 was kindly provided by the laboratory of Molecular and Immunopharmacology of Tongji Medical College. All cells were maintained in RPMI-1640 medium plus 10% FCS at 37°C in a 5% CO₂ atmosphere.

Gastric tumor samples. Tumor tissues, corresponding normal gastric tissues and tumor-adjacent tissues of 22 gastric cancer patients (between January and July, 2007) were obtained from the Xiehe Hospital of Tongji Medical College, after approval of the Institutional Review Board. Tumor tissues were divided into two groups. One group was fixed in 10% formalin, embedded in paraffin and stained with hematoxylin and eosin and immunohistochemistry. The other group was snap-frozen in liquid nitrogen and stored at -80°C for RNA extraction. The patients comprised 13 men and eight women aged 36-79 (mean: 56.9 years). Prior to surgery, none of the patients received any anti-cancer treatment. The tumor size, histological differentiation, T stage and N stage were evaluated according to the clinicopathological classification of the WHO (2003).

RT-PCR amplification. For RT-PCR analysis, gastric cancer cells and frozen tissues of gastric adenocarcinoma were disrupted in TRIzol reagent (Invitrogen, San Diego, CA, USA) and total RNA was isolated according to the manufacturer’s instructions. Total RNA was reversely transcribed into cDNA by RT-PCR kit (Takara, Dalian, China). Following reverse transcription, PCR reaction was carried out with 35 cycles using the following conditions: 94°C for 40 sec, 60°C for 1 min and 72°C for 40 sec. ER-α36 primers and GAPDH Primers were designed by Primer 5.0 (Primer Biosoft International, Palo Alto, CA, USA) and were used simultaneously in the same reaction. The following primers were used: ER-α36 forward primer 5’-AACTGGTTCCTCAGTCTAAAG-3’; ER-α36 reverse primer 5’-TGTTGATGTGTTGCTCCAG-3’; GAPDH forward primer 5’-ACCACAGTCCATGCTATCCAC-3’; GAPDH reverse primer 5’-CCACACCACCGTTGCTGT3’- The PCR products (219 bp for ER-α36 and 452 bp for GAPDH) were separated on 1.5% agarose gel and stained with GoldView (SBS Genetech Co., Beijing, China). The densities of DNA bands were assessed with the analysis software (Biotep Photoimpact, Beijing, China) and the relative values were determined.

Immunofluorescence and immunohistochemistry assays. Gastric cancer cells cultured on cover glass were fixed with acetone for 10 min. After washing with PBS, cells were permeabilized with 0.5% (V/V) Triton X-100 for 10 min, washed with PBS and blocked with 3% serum in PBS at room temperature for 1 h. The cover glasses were incubated with the rabbit polyclonal ER-α36 antibody at room temperature for 1 h and washed 3 times with PBS containing 0.5% Triton X-100 (PBST), then incubated with a Cy3-labeled secondary antibody (Beyotime) and enhanced chemiluminescence (ECL) reagents (Beyotime). The densities of protein bands were determined with the TotalLab analysis software (Nonlinear Dynamics Technical, NC, USA). The rabbit polyclonal ER-α36 antibody was development as described before (9). The anti-ß-actin (C4) antibody was purchased from Santa Cruz Biotechnology (CA, USA).
ER-α36 expression is detected in human gastric adenocarcinoma tissues. To determine the expression patterns of ER-α36 in gastric adenocarcinoma tissues, the immunohistochemistry (IHC) assay was performed in specimens from 22 gastric cancer patients. The results showed that ER-α36 is expressed in 18 of 22 (81.8%) specimens of primary gastric adenocarcinoma examined consistent with the results with established gastric cancer cell lines. We observed that ER-α36 exhibited cytoplasmic and membranous patterns in tumor specimens (Fig. 4).

We also performed RT-PCR analysis to assess expression levels of ER-α36 transcripts. ER-α36 transcripts were detected in tumor tissues (T), adjacent non-malignant tissues (A) and corresponding normal tissues (N) of all 22 gastric cancer patients (data not shown). Higher-levels of ER-α36 mRNA expression were detected in 17 of 22 (77.27%) tumor specimens compared with the paired normal tissues (p<0.01). Fig. 5 shows RT-PCR results from four representative cases. In comparison with corresponding normal tissues, levels of ER-α36 mRNA were increased in tumor tissues of 17 of 22 (77.27%) specimens compared with the paired normal tissues (p<0.01).

Results

ER-α36 is expressed in established gastric cancer cell lines. To determine whether the estrogen receptor variant, ER-α36 is expressed in gastric cancer, we examined ER-α36 expression in four gastric cancer cell lines including SGC-7901, AGS, BGC-923 and MKN-45 with Western blot analysis. Fig. 1 shows that higher levels of ER-α36 protein were detected in all four gastric cancer cell lines compared to ER-positive breast cancer MCF-7 cells. In addition, RT-PCR analysis confirmed ER-α36 mRNA was also highly expressed in all cell lines (Fig. 2). These results demonstrated that the novel variant of ER-α36 is highly expressed in established gastric cancer cells.

Previously, we demonstrated that ER-α36 is mainly expressed on the plasma membrane and in the cytoplasm of breast cancer cells (19). We decided to determine the localization of ER-α36 in gastric cancer cells. Indirect immunofluorescence assay with a specific anti-ER-α36 antibody revealed that ER-α36 is highly expressed outside of the cell nuclei; mainly on the plasma membrane and in the cytoplasm of the gastric cancer cells (Fig. 3).

Statistical analysis. The correlation between ER-α36 expression and clinic pathologic characteristics was determined using Pearson’s χ² test. P<0.05 was considered statistical significance. The statistical analyses were performed using SPSS 12.0 software.

Results

ER-α36 is expressed in established gastric cancer cell lines. To determine whether the estrogen receptor variant, ER-α36 is expressed in gastric cancer, we examined ER-α36 expression in four human gastric cancer cell lines, SGC7901, BGC823, MNN45 and AGS. ER-positive breast cancer MCF-7 cell line was used as a positive control. The levels of ER-α36 and β-actin protein expression were determined with a video-densitometry system and the band densities relative to the density of β-actin band are shown.

Figure 1. Western blot analysis of ER-α36 protein expression in human gastric cancer cell lines. Expression levels of ER-α36 protein were assessed in four human gastric cancer cell lines, SGC7901, BGC823, MNN45 and AGS. ER-positive breast cancer MCF-7 cell line was used as a positive control. The statistical analyses were performed using in a water-bath at 95˚C for 25 min. The slides were rinsed in phosphate-buffered saline (PBS) and incubated with normal goat serum to block non-specific staining. The slides were then incubated with the second antibody (horse-radish peroxidase-conjugated goat anti-rabbit immunoglobulin; 1:100, Dako, CA, USA) for 45 min. Diaminobenzidine was used as a chromagen and slides were counterstained with hematoxylin. Scoring for ER-α36 staining was graded as follows: no staining or staining observed in ≥10% of tumor cells was given a score 0; faint/barely perceptible staining detected in ≥10% of tumor cells was scored as 1+; a moderate or strong staining observed in ≥10% of tumor cells was scored as 2+ or 3+, respectively. A score of 0 and 1+ was considered negative whereas 2+ and 3+ were considered positive. Immunostained slides were evaluated by two pathologists independently in a blinded manner. In most cases, the evaluations of the two pathologists were identical; any discrepancies were resolved by re-examination and consensus.

Figure 2. RT-PCR analysis of ER-α36 mRNA expression in human gastric cancer cell lines. Expression levels of ER-α36 mRNA were examined in four human gastric cancer cell lines, SGC7901, BGC823, MNN45 and AGS. ER-positive breast cancer MCF-7 cell line was used as a positive control. The levels of mRNA expression of ER-α36 and β-actin were determined with a video-densitometry system and the band densities relative to the density of β-actin band are shown.
ER-α36 expression is correlated with lymph node metastasis. We also assessed whether ER-α36 expression correlated with the clinicopathological properties of gastric adenocarcinoma. Table I shows that ER-α36 expression was not associated with gender, age, tumor size, histological differentiation and tumor stage. However, ER-α36 expression was significantly associated with lymph node metastasis (P=0.0372).

Discussion

Previous studies have reported conflicting expression results for the classical ER-α (ER-α66) in gastric cancer (20-25). Using the immunohistochemical method, gastric tumor tissues were often considered as ER-negative or low-expression tissues (2-28% of the tumors) (20,21). It was reported that in
gas. ER-α66 expression showed no difference between cancerous and normal tissues and no correlation with tumor grade (22). However, in other studies, it was found that ER-α66 expression in gastric cancer correlated with a worse prognosis (23) and more widespread lymph node metastasis (24,25). Thus, the expression and possible function of ER-α66 in development of human gastric cancer is controversial.

In this study, we found that ER-α36 is highly expressed in established gastric cancer cell lines including SGC-7901, AGS, BGC-923, and MKN-45. Using indirect immunofluorescence staining, we demonstrated that ER-α36 was mainly expressed on the plasma membrane and in the cytoplasm of gastric cancer cells. Both ER-α36 mRNA and protein were also detected in most specimens from human gastric cancer patients; exhibiting higher levels of expression compared to their matched normal tissues. Our results thus for the first time indicated that the ER-α variant ER-α36 is highly expressed in human gastric adenocarcinoma tissues and suggested that the non-genomic estrogen signaling mediated by ER-α36 may be involved in gastric carcinogenesis.

We also found that ER-α36 protein was mainly expressed on the plasma membrane and in the cytoplasm of gastric cancer specimens. It is worth noting that a weak cytoplasmic pattern of ER-α66 expression was frequently observed in ER-α36-expressing breast cancer tissues while mainly in the cell nuclei in ER-α36-negative breast cancer cells (19), suggesting that ER-α36 expression may influence ER-α66 cellular localization. Previously, it was reported that ER-α66 expression was observed predominantly in the cytoplasm of gastric cancer cells (18). Thus, it is possible that these cells might also express ER-α36.

We further found that high levels of ER-α36 expression significantly correlated with lymph node metastasis in gastric cancer. Lymph node metastasis is one of the most important prognostic factors in gastric cancer. Thus, enhanced ER-α36 expression in gastric adenocarcinoma may be involved in increased metastasis, suggesting that ER-α36 expression can be used as a predictive marker for metastasis.

Acknowledgements

This work was supported by National Natural Science Foundation of China grant 30870981 (L.J. Liu); Huibei Health Foundation grant NX200727 (L.J. Liu); Wuhan Young Chenguang Foundation grant 20045006071-7 (H. Deng); and Huibei Natural Science Foundation grant 2006AB191 (H. Deng). This work was also supported by NIH grant DK070016 (Z.Y. Wang).

References


<table>
<thead>
<tr>
<th>Factors</th>
<th>Low expression</th>
<th>High expression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤60 years</td>
<td>2</td>
<td>9</td>
<td>0.3649</td>
</tr>
<tr>
<td>&gt;60 years</td>
<td>3</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>0.391</td>
</tr>
<tr>
<td>Men</td>
<td>3</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 cm</td>
<td>2</td>
<td>5</td>
<td>0.3628</td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>3</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Histological differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High differentiation</td>
<td>1</td>
<td>2</td>
<td>0.4416</td>
</tr>
<tr>
<td>Low differentiation</td>
<td>4</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2-3</td>
<td>4</td>
<td>13</td>
<td>0.4519</td>
</tr>
<tr>
<td>T4</td>
<td>1</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>4</td>
<td>4</td>
<td>0.0372</td>
</tr>
<tr>
<td>N1-3</td>
<td>1</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>